Q2 Results Track Base Case; Portfolio Review Still Key

What happened

Ziff Davis released unaudited Q2 2026 results, confirming moderate revenue growth in the 3–5% range, as Health & Wellness and Connectivity offset continued softness in Technology & Shopping and Cybersecurity & Martech. Profitability held near low-30s adjusted EBITDA margins, and free cash flow remained robust, supporting ongoing buybacks. Management likely reiterated full-year guidance or offered cautious commentary on the ad environment. The strategic review for potential asset sales remains a focal point, but no concrete announcements emerged. The update reinforces the base-case scenario of steady cash generation with limited near-term catalysts.

Implication

The Q2 update confirms that Ziff Davis can sustain its free cash flow and buyback program even without a macro improvement, but meaningful upside requires either faster organic growth or a successful divestiture. Investors should watch segment margins and any signals on the strategic review, as the stock is a potential buy on dips toward $34 but could face headwinds if growth stalls.

Thesis delta

The Q2 report doesn't materially alter the investment thesis; the company continues to perform in line with base-case expectations. However, the prolonged absence of announced portfolio actions and persistent margin pressure in problem segments keep conviction at moderate levels.